Contract Services Contract Research

WuXi AppTec Breaks Ground on New R&D and Manufacturing Site in Singapore

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life scie...

 May 24, 2024 | News

Allucent Secures $25.5 Million Award for Decentralized COVID-19 Trial

 Allucent, a global mid-sized clinical research organization (CRO), announced  that it received a project award valued at $25.5 million...

 May 16, 2024 | News

AGC Biologics Completes Production of VAR2 Pharmaceuticals' Cancer-Targeting Antibodies

AGC Biologics announced the completion of work with VAR2 Pharmaceuticals on the production of the company’s two antibody candidates targeti...

 April 25, 2024 | News

WuXi AppTec's Changzhou Facility Gains PMDA Approval, Bolstering Global Expansion Plans

Latest regulatory approval follows on the back of expansion plans announced during DCAT 2024   With peptides, oligos and peptide conjugates continui...

 April 22, 2024 | News

Invenra and Catalent Forge Partnership to Advance Cancer Treatment Innovations

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Dev...

 April 03, 2024 | News

Resonance Health Joins Forces with Micron, Inc. for Strategic Entry into Japan's Healthcare Sector

Resonance Health Ltd, listed on the Australian Securities Exchange (ASX) under the ticker RHT, has officially announced its strategic move into the Japanes...

 March 28, 2024 | News

Aragen Biologics Launches First Phase of New Facility in India, Spearheading Novel Anticancer mAb Manufacturing

Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, announced that it has operat...

 March 28, 2024 | News

DigmBio's Breakthrough Cancer Drug Clears Korean Regulatory Hurdle

BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breas...

 March 26, 2024 | News

WuXi Biologics Breaks Ground on State-of-the-Art $1.4 Billion CRDMO Facility in Singapore

WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced ...

 March 19, 2024 | News

WuXi Biologics attains leadership status in 2023 CDP Climate Change evaluation

  CDP runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impact. In 2023, more than...

 March 06, 2024 | News

Medidata and Sanofi Boost Trial Efficiency with Expanded Patient-Centric Collaboration

 Medidata, a Dassault Systèmes subsidiary and a leading provider of clinical trial solutions for the life sciences industry, today announced a ...

 February 29, 2024 | News

RSSL Launches Innovation Hub for Biotech Support with Labs and Services

  RSSL’s Innovation Hub will be a supportive ecosystem for early-stage biotech companies, providing a wide range of tailored services to help t...

 February 22, 2024 | News

WuXi Biologics Achieves Milestone with 16,000L Manufacturing Run in Ireland

First manufacturing run successful for MFG7 facility at the Ireland site Largest manufacturing scale to date achieved by combining four 4,000-liter sing...

 February 01, 2024 | News

WuXi XDC Partners with Multitude and HySlink for Accelerated ADC Discovery and Development

WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. As WuXi XDC's strategic partner, Multitude Therapeu...

 January 31, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close